Business Description
Cardiol Therapeutics Inc
NAICS : 325410
SIC : 3741
ISIN : CA14161Y2006
Share Class Description:
CRDL: Class ATotal Employee Number:
18Compare
Compare
Traded in other countries / regions
CRDL.CanadaCRDL.USACT9.Germany IPO Date
2019-01-15Description
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 236.52 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.8 | |||||
3-Year EPS without NRI Growth Rate | 15.2 | |||||
3-Year FCF Growth Rate | 14.3 | |||||
3-Year Book Growth Rate | -39.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 46.27 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.8 | |||||
9-Day RSI | 34.4 | |||||
14-Day RSI | 34.87 | |||||
3-1 Month Momentum % | -20.71 | |||||
6-1 Month Momentum % | 9.9 | |||||
12-1 Month Momentum % | -23.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.39 | |||||
Quick Ratio | 4.39 | |||||
Cash Ratio | 3.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.1 | |||||
Shareholder Yield % | -8.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -224.28 | |||||
ROA % | -160.32 | |||||
ROIC % | -2642.07 | |||||
3-Year ROIIC % | 569.81 | |||||
ROC (Joel Greenblatt) % | -23888.59 | |||||
ROCE % | -218.31 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.73 | |||||
Price-to-Tangible-Book | 6.8 | |||||
EV-to-EBIT | -3.78 | |||||
EV-to-Forward-EBIT | -3.39 | |||||
EV-to-EBITDA | -3.79 | |||||
EV-to-Forward-Revenue | 8.36 | |||||
EV-to-FCF | -5.54 | |||||
| Price-to-Net-Current-Asset-Value | 6.8 | |||||
| Price-to-Net-Cash | 7.85 | |||||
Earnings Yield (Greenblatt) % | -26.46 | |||||
FCF Yield % | -15.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRDL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cardiol Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.284 | ||
| Beta | 1.3489 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.61 | ||
| Volatility % | 51.3 | ||
| 14-Day RSI | 34.87 | ||
| 14-Day ATR ($) | 0.056075 | ||
| 20-Day SMA ($) | 1.052 | ||
| 12-1 Month Momentum % | -23.45 | ||
| 52-Week Range ($) | 0.88 - 1.71 | ||
| Shares Outstanding (Mil) | 115.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cardiol Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cardiol Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 37 days | ||
| General meeting for 2026 | 2026-06-24 16:30 | 1.05 (-0.94%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 13:30 | 1.28 (-3.76%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.32 (-0.75%) | ||
| Annual report for 2025 | 2026-03-31 | 1.22 (-2.40%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 10:30 | 1.01 (+1.00%) | ||
| Cardiol Therapeutics Presentation of Phase II ARCHER Trial Results | 2025-12-01 08:30 | 1.05 (+1.94%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.04 (+0.97%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.11 (-5.93%) |
Show
Entries
Cardiol Therapeutics Inc Frequently Asked Questions
What is Cardiol Therapeutics Inc(CRDL)'s stock price today?
The current price of CRDL is $1.02. The 52 week high of CRDL is $1.71 and 52 week low is $0.88.
When is next earnings date of Cardiol Therapeutics Inc(CRDL)?
The next earnings date of Cardiol Therapeutics Inc(CRDL) is 2026-08-14 Est..
Does Cardiol Therapeutics Inc(CRDL) pay dividends? If so, how much?
Cardiol Therapeutics Inc(CRDL) does not pay dividend.
Guru Commentaries on NAS:CRDL
No articles.
Press Release
Articles on Cardiol Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers